BridgeBio Pharma, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BBIO research report →
Range $87 – $156
Price Chart
About the company
BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts an extensive portfolio comprising 30 distinct development initiatives, spanning the entire spectrum from initial discovery research to advanced clinical trial phases.
- CEO
- Neil Kumar
- IPO
- 2019
- Employees
- 1,001
- HQ
- Palo Alto, CA, US
AI snapshot
Six angles, distilled from the data.
BBIO remains in a constructive multi-month uptrend, trading above its 50-day and 200-day moving averages. The stock is still below its 52-week high of 93.42, but well above the 52-week low of 62.5, which points to a strong recovery phase rather than a breakout extension.
Street sentiment stays favorable, with a Buy consensus and an average target of 110.18, above the current setup. Recent actions were mostly reiterations, while several targets were trimmed modestly, suggesting confidence remains intact even as expectations are being refined.
The latest quarter beat by 30.0%, but the broader pattern is uneven, with only 2 of the last 8 quarters topping estimates. Next-year EPS is still expected to improve from -3.04 TTM to -0.2733, so shareholders should watch for continued margin progress and execution consistency.
The pattern is net selling, led by repeated CEO disposals and one CAO sale, which leans negative on discretionary signal. Most other entries are automatic or non-discretionary flows tied to awards, exemptions, or in-kind activity, so the main takeaway is insider monetization rather than broad-based buying.
Profitability is still weak despite strong gross economics, with a 94.3% gross margin offset by a -37.34% operating margin and -59.84% net margin. Revenue growth is positive at 192.6% year over year, but operating cash flow was -445.9 million and free cash flow was -444.8 million in 2025.
BBIO screens as a high-growth biotech with better top-line momentum than most mature peers, but it still carries negative earnings and cash flow. Versus the sector, the setup favors premium expectations: the market is paying for pipeline execution, not current profitability.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $14.81B
- P/E
- -25.65
- Fwd P/E
- 23.56
- PEG
- -0.77
- P/S
- 16.06
- P/B
- -9.19
- EV/EBITDA
- -36.65
- Div Yield
- 0.00%
- Gross Margin
- 93.51%
- Op Margin
- -43.35%
- Net Margin
- -60.30%
- ROE
- 26.76%
- ROIC
- -23.63%
Latest fiscal year · YoY change
- Revenue
- $502.08M+126.3%
- Gross Profit
- $473.81M+117.3%
- Op Income
- $-569,087,000
- Net Income
- $-729,306,000-36.1%
- EPS
- $-3.79-31.6%
- OCF Growth
- +14.4%
- FCF Growth
- +14.3%
- 52W High
- $93.42
- 52W Low
- $62.50
- 50D MA
- $70.22
- 200D MA
- $72.70
- Beta
- 0.97
- RSI (14)
- 55
- Avg Volume
- 2.67M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
BridgeBio reported strong Q3 revenue growth led by Attruby, while also highlighting a near-term pipeline of three potential launches and a record cash position.· October 29, 2026
- Attruby U.S. net product revenue reached $253.2 million, up 14% sequentially and 134% year over year.
- Management said Attruby is gaining most in first-line use and reiterated a $25 million to $30 million near-term quarterly growth expectation.
- BridgeBio highlighted new real-world data showing acoramidis outperformed tafamidis on multiple outcomes, including hospitalization and clinical worsening.
- BBP-418 has a November 27 PDUFA date, infigratinib has a February 4, 2027 PDUFA date, and encaleret has a May 8, 2027 PDUFA date, all under priority review.
- Cash, cash equivalents and marketable securities were $1.5 billion, which management called the strongest cash position in company history.
Total revenues were $353.2 million in Q3 2026 versus $120.7 million in Q3 2025. U.S. Attruby net product revenue was $253.2 million versus $108.1 million a year ago, and royalty revenue was $20.5 million versus $4.3 million a year ago. Total operating expenses were $344.4 million versus $259.3 million last year, and loss from operations improved to $11.6 million from $145.2 million. Management said the revenue increase was driven by Attruby growth and a $75 million one-time BEYONTTRA sales milestone, and it expects OpEx to catch up in Q4 before more modest growth and improving operating leverage through 2027. For the near term, management reiterated BBP-418’s November 27 PDUFA date, infigratinib’s February 4, 2027 PDUFA date, and encaleret’s May 8, 2027 PDUFA date. As for Attruby, management said $25 million to $30 million quarterly growth is the right near-term base.
Neil Kumar framed the quarter as evidence that BridgeBio is entering a new phase, with Attruby annualizing to over $1 billion in the U.S. and well over that globally. He emphasized that the company believes Attruby remains on track to meet or beat its $4 billion peak-year sales assumption, supported by first-line momentum, real-world evidence, and a changing reimbursement environment. His tone was confident and expansive, with strong focus on the platform value of the portfolio and on multiple launches ahead.
Tom Trimarchi said the quarter reflected strong revenue growth, disciplined spending, and a healthier balance sheet. He cited $353.2 million of total revenue, $344.4 million of operating expenses, an $11.6 million operating loss, and $1.5 billion of cash, cash equivalents and marketable securities as of September 30, 2026. He said the company should average an operating loss of about $90 million to $100 million per quarter this year, improving from about $130 million per quarter last year, and expects continued margin expansion toward breakeven in 2027.
Analysts focused on Attruby’s quarterly growth rate, payer restrictions, the capital allocation strategy, and the launch outlook for BBP-418, infigratinib, and encaleret. Management said $25 million to $30 million is the near-term Attruby growth base, with more upside over time from first-line penetration, broader prescriber education, and continued use of the real-world evidence package. On access, management said United has not made any new 2026 change affecting Attruby and that approval rates through appeal are above 90%. On BBP-418, management said it expects traditional full approval on November 27; on infigratinib, it said the citizen petition should not affect review timing or labeling; and on encaleret, it said the RECLAIM-HP trial is powered on concomitant normalization of blood and urine calcium with a 3:1 randomization.
The bull case from this call is that Attruby continues to post very strong growth while management believes the launch still has a long runway, especially in first-line prescribing and among the long tail of untreated physicians. BridgeBio also pointed to multiple external data sets showing better outcomes versus tafamidis, which it says should support share gains and pricing power over time. Beyond Attruby, the company is heading into three priority-review regulatory events and says its balance sheet is sufficient to fund them.
The main risks are that Attruby growth could moderate from here, with management itself saying $25 million to $30 million quarterly growth is the near-term base. The company also acknowledged the long tail of prescribers is still largely untapped and that payer and competitive dynamics can shift, even if it says Attruby has not been newly affected by restrictions. On the pipeline, BBP-418, infigratinib and encaleret still depend on pending FDA decisions, and encaleret’s broader chronic hypoparathyroidism program will not read out top-line results for about 15 months.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 83.7%
- Shares Outstanding
- 194.80M
- Float Shares
- 163.00M
of shares held by institutions
516 13F filers
Buy/sell ratio 0.36. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for BBIO, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Gilbert CisnerosHouse · CA31 | Buy | Oct 27, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Nov 2, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Sell | Sep 29, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | May 11, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Apr 29, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Mar 3, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Mar 18, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Mar 19, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Sep 22, 25 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Aug 8, 25 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 16.86M | ▲ 30.63K |
| Jupiter Topco LLC | 14.11M | ▲ 14.11M |
| Janus Henderson Group Ltd. | 13.18M | ▲ 2.18M |
| Farallon Capital Management, L.L.C. | 10.74M | ▲ 1.38M |
| Blackrock, Inc. | 10.39M | ▲ 101.53K |
| Viking Global Investors LP | 9.95M | ▼ 1.89M |
| Kohlberg Kravis Roberts & Co. L.P. | 8.26M | ▼ 5.00M |
| Vanguard Capital Management LLC | 7.91M | ▲ 15.13K |
| Vanguard Portfolio Management LLC | 7.49M | ▼ 171.52K |
| Wellington Management Group Llp | 5.31M | ▲ 2.82M |
| State Street Corp | 4.98M | ▲ 541.23K |
| Two Sigma Investments, LP | 4.72M | ▲ 1.60M |
Held by 526 ETFs
Biggest fund positions in BBIO by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 18, 26 | Kumar Neil | sell | 1,277 |
| Nov 18, 26 | Kumar Neil | sell | 8,723 |
| Nov 19, 26 | Kumar Neil | sell | 8,500 |
| Nov 19, 26 | Kumar Neil | sell | 1,500 |
| Nov 18, 26 | Kumar Neil | sell | 4,490 |
| Nov 18, 26 | Kumar Neil | sell | 30,490 |
| Nov 16, 26 | Trimarchi Thomas | other | 22,781 |
| Nov 16, 26 | Apuli Maricel | other | 4,714 |
| Nov 16, 26 | Kumar Neil | other | 6,519 |
| Nov 16, 26 | Kumar Neil | other | 11,554 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BBIO coverage
Recent articles, reports, and earnings notes.

BridgeBio Pharma (BBIO): Attruby Growth Meets Heavy Risk
BridgeBio Pharma is transitioning into a commercial biotech, led by rapid Attruby sales growth and a late-stage pipeline. But losses, debt, and regulatory execution risk keep the stock at Hold.

Nordicus Partners IPO: What Investors Need to Know
Nordicus Partners Corporation (NASDAQ: NORD) is expected to list on 2026-10-30, but the company has not disclosed a price range yet. The story is less a classic IPO and more a microcap biotech holding-company setup tied to Nordic life sciences assets. Bull case: asset-backed biotech optionality; bear case: no disclosed terms, nominal revenue, and going-concern risk.

ADARx Pharmaceuticals IPO Preview: RNA Pipeline Meets Cash Burn
ADARx Pharmaceuticals is expected to list on NASDAQ on 2026-09-25, with shares priced in a $15.00 to $17.00 range. The company is offering 21,875,000 shares and has disclosed an implied market cap of $427,656,250. The setup favors investors who want late-stage RNA exposure, but the key watch item is whether the market gives credit to the pipeline before more clinical data arrives.
Want a deeper read on BBIO?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Acoramidis Was Associated with Lower Risk of Worsening Heart Failure Versus Tafamidis in Real-World Study and Reduced Heart Failure Events Within One Month in ATTRibute-CM
globenewswire.com · Nov 17
BridgeBio Pharma, Inc. (BBIO) Presents at Jefferies Global Healthcare Conference 2026 Transcript
seekingalpha.com · Nov 16
NVIDIA (NASDAQ:NVDA) Stock Sale Disclosed by Rep. Gilbert Ray Cisneros, Jr.
defenseworld.net · Nov 13
BridgeBio to Present New Acoramidis Data on Kidney Function, Real-World Outcomes, and First-Line Treatment Patterns in ATTR-CM at the International Symposium on Amyloidosis 2026
globenewswire.com · Nov 11
BridgeBio to Participate in November and December Investor Conferences
globenewswire.com · Nov 9
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Nov 6
BridgeBio to Present New Acoramidis Data on Heart Failure Events in ATTR-CM at the American Heart Association Scientific Sessions 2026
globenewswire.com · Nov 3
Should You Invest $1,000 in BridgeBio Pharma Right Now?
fool.com · Nov 2
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 14, 2026 · Live quote · Not investment advice